Amira Pharmaceuticals, Inc. announced initial positive data from a Phase 1 clinical study of AM152, an oral, selective antagonist of the LPA1 receptor. This study positions Amira to initiate a Phase 2a trial in patients suffering from systemic sclerosis.
Xenon Pharmaceuticals Inc. announced that its novel ointment XEN402 demonstrated significant and clinically meaningful reductions in pain in patients with postherpetic neuralgia.
Abbott Laboratories said that it received U.S. regulatory approval for a new, more potent formulation of its testosterone gel. The gel is approved for men with hypogonadism or low testosterone.
British drugmaker AstraZeneca PLC said that U.S. regulators approved an injectable version of its heartburn drug Nexium for use in infants as young as a month old.
Fitch Ratings said it is considering downgrading certain ratings for Johnson & Johnson, citing the company's move to buy Swiss medical device maker Synthes Inc. for $21.3 billion.
Keryx Biopharmaceuticals Inc. said it was informed by a European Union advisory committee that if its current late-stage clinical trial is successful, that study would provide enough data to support a marketing application in the EU
Watson Pharmaceuticals Inc. said it has started selling an authorized generic version of Johnson & Johnson's attention deficit hyperactivity disorder drug Concerta. Watson said sales of Concerta, or methylphenidate, totaled $1.5 billion in the last year.
Teva Pharmaceutical Industries Ltd. has agreed to buy Cephalon Inc. for $6.8 billion in a deal that would give the world's largest generic drug developer a range of biotechnology drugs aimed at cancer and other conditions.
A technology upgrade service from Fluid Imaging Technologies enables FlowCAM particle imaging and analysis system users to install many of the company’s latest advances on their existing models.
NanoSight announced the release of their latest NS200 nanoparticle characterization system, which features a high sensitivity camera built into the housing of the system.
Whitehouse Scientific offers a paper reviewing the development of reference standards over three decades.
The California Institute for Quantitative Biosciences (QB3) has entered into a collaboration with Deloitte to help the institute in its efforts to convert bioscience innovation into a driver for jobs, companies and improved health in California.
Acura Pharmaceuticals Inc. said that President and CEO Andrew Reddick died Thursday. He was 58.
QRxPharma Limited has completed patient enrolment for Study 022, a Phase 3 trial comparing the tolerability and safety profile of MoxDuo IR to equi-analgesic doses of either morphine or oxycodone alone.
Anavex Life Sciences Corp. announced that the first healthy human volunteers have been initially dosed in its Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease.